Project

Discovery of therapeutic antibody candidate with the mechanism of controlling reactive gliosis

Project Summary

Multiple Sclerosis (MS) is a demyelinating disease in which the insulating covers of the nerve cells in the brain and the spinal cord are damaged. It causes disruption in the nerve system leading to physical, mental and sometimes psychiatric problems.

Currently there is a gap in the treatment of MS as the currently available drugs are only able to delay the progression of the disease rather than cure the core cause of the disease.
Neuracle Science with the funding of the TIPS program aims to discover the lead candidate in developing its therapeutic antibody for treatment of CNS diseases with focus in Multiple Sclerosis.

We have currently identified the lead candidate and is in the cell development stage.

Business Model

Profit Source: License out of technology to a Multinational pharmaceutical company
Key Clients: Multinational pharmaceutical company/ Multiple Sclerosis patients
Key Channels: International Biotech conferences / Neurology
Core Activities: Cooperation with biologics specialized CROs and Co-Research with Dr. Jaeyoung Seong of Korea University.

Main Achievements

Patent Registration:
Korea (1), US (1),
Provisional Patent Application:
US (3), PCT (1)
Funding:
2016.05 5th round funding – 42.4million won / QUAD Investment
2016.12 6th round funding – 34million won / Private Investor
2017.03 Convertible Bond – 20million won/ Timewise Investment
2018.01 7th round funding - 100million won / Braman Investment
Recruitment:
12 employees